Related Experiment Video
Updated: Jun 6, 2025

09:04
A Simple Bioassay for the Evaluation of Vascular Endothelial Growth Factors
Published on: March 15, 2016
9.7K
Molecular Characterization and Interaction between Human VEGF-D and VEGFR-3
Chae Eun Seo1, Han Na Lee2, Mi Suk Jeong2
1Department of Molecular Biology, College of Natural Sciences, Pusan National University, Busan 46241, Republic of Korea.
Journal of Microbiology and Biotechnology
|November 27, 2024
Summary
Vascular Endothelial Growth Factor D (VEGF-D) and its receptor VEGFR-3 are key in cancer metastasis. Researchers identified critical residues for their interaction, paving the way for metastasis-inhibiting peptides.
Area of Science:
- Molecular Biology
- Cancer Research
- Biochemistry
Background:
- Metastasis involves angiogenesis and lymphangiogenesis, processes stimulated by Vascular Endothelial Growth Factors (VEGFs) binding to their receptors.
- VEGF-D and its receptor VEGFR-3 are crucial for cellular processes like survival, proliferation, and migration, significantly impacting lymphangiogenesis and cancer spread.
Purpose of the Study:
- To elucidate the molecular characteristics of VEGF-D and VEGFR-3 proteins.
- To pinpoint essential amino acid residues responsible for the VEGF-D/VEGFR-3 interaction.
Main Methods:
- Size exclusion chromatography was employed to analyze protein characteristics.
- GST pull-down assays were utilized to investigate the binding interaction between VEGF-D and VEGFR-3.
Main Results:
- Specific residues, notably D103 and Q110 in VEGF-D, were identified as critical for VEGFR-3 binding.
- Mutations at these key residues led to structural changes, reduced binding affinity, and impaired VEGFR-3 activation.
- A synthesized peptide, based on these key residues, demonstrated potential in inhibiting VEGF-D/VEGFR-3 interaction.
Conclusions:
- The study identified key residues essential for VEGF-D and VEGFR-3 interaction, providing molecular insights into lymphangiogenesis.
- These findings support the development of therapeutic peptides targeting the VEGF-D/VEGFR-3 pathway to suppress cancer metastasis.
- The research highlights a potential strategy to inhibit cancer cell-induced lymphangiogenesis and combat metastasis across various cancer types.

